Qiming Venture Partners

Founded 2006


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 635
Average round size
The average size of a deal this fund participated in
Portfolio companies 379
Rounds per year 42.33
Lead investments 201
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 51
Key employees 12
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Health Care
  • Medical
  • Biotechnology
  • Internet
  • Software

In 2006 was created Qiming Venture Partners, which is appeared as VC. The main office of represented VC is situated in the Shanghai. The fund was located in Asia if to be more exact in China.

Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Internet, Biotechnology. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. Among the most popular portfolio startups of the fund, we may highlight Xiaomi, Meituan-Dianping, ChinaCache. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.

When the investment is from Qiming Venture Partners the average startup value is more than 1 billion dollars. Opposing the other organizations, this Qiming Venture Partners works on 21 percentage points less the average amount of lead investments. The real fund results show that this VC is 5 percentage points more often commits exit comparing to other companies. The top amount of exits for fund were in 2018. The fund is generally included in 25-48 deals every year. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. Deals in the range of 10 - 50 millions dollars are the general things for fund.

Besides them, we counted 12 critical employees of this fund in our database.

The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Qiming Venture Partners, startups are often financed by K2VC, China Growth Capital, Kleiner Perkins. The meaningful sponsors for the fund in investment in the same round are TF Capital, Northern Light Venture Capital, Kleiner Perkins. In the next rounds fund is usually obtained by Matrix Partners China, Goldman Sachs, GGV Capital.

Read more

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation


Artificial Intelligence
Health Care
$15M25 Aug 2021 China, Beijing


Cloud Computing
Cloud Management
Information Technology
$10M24 Aug 2021 United States, " United States"}

Berry Oncology

Health Care
Medical Device
$99M05 Aug 2021 China, Fuzhou


Consumer Goods
$100M15 Jul 2021 China, Shanghai

Hochuen Medical Technology

$40M12 Jul 2021 China, Shenzhen

Insilico Medicine

Artificial Intelligence
Health Care
$255M22 Jun 2021 China, Hong Kong Island

Xiaoe Tech

$120M16 Jun 2021 China, Futian District


Health Care
Medical Device
$42M26 May 2021 China, Gusu District


Artificial Intelligence
Autonomous Vehicles
13 May 2021 China, Yuexiu District
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

Berry Oncology Closes US$99.15M Series B1 Funding

– Berry Oncology Corporation, a member company of China’s leading early cancer screening firm Berry Genomics, closed a US$99.15m Series B1 financing round.
– This round was led by China Merchants Capital Management Co., Ltd. Existing investors Qiming Venture Partners and Legend Capital, along with new investors including Zhongjin Qichen Industry Equity Investment Fund, E Fund, Fujian Venture Investment Management Co., Ltd., Xiamen C&D Emerging Industry Equity Investment Co., Ltd. and other investors also participated.
– The new proceeds will enable the company to meet the demand for early cancer screening and diagnosis and boost its expansion in the market.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Qiming Venture Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: